SCM
LGND icon

Scopia Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Scopia Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,167,886
Closed -$88.4M – 37
2017
Q2 		$88.4M Sell
1,167,886
-697,737
-37% -$48.8M 1.82% 23
2017
Q1 		$123M Buy
1,865,623
+1,031,345
+124% +$67.8M 2.28% 17
2016
Q4 		$52.9M Buy
+834,278
New +$52.6M 1% 25

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Scopia Capital Management's LGND Position: Q3 2017 in Review

Scopia Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2017, closing a stake of 1,167,886 shares — an estimated $88.4M sold.

Scopia Capital Management first reported a position in LGND in Q4 2016 and held it in 3 quarters. The position peaked at $123M in Q1 2017. 293 funds tracked by Wall St. Rank hold LGND as of Q3 2017.

  • Scopia Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Scopia Capital Management sold 1,167,886 Ligand Pharmaceuticals shares in Q3 2017, an estimated $88.4M.
  • Scopia Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Scopia Capital Management's Ligand Pharmaceuticals position peaked at $123M in Q1 2017.
  • 293 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2017.

Based on Scopia Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.